June 2020 Hematology and Oncology journal

Advances in CAR T-Cell Therapy for the Treatment of Multiple Myeloma

Nina Shah, MD

  H&O  What is the rationale for the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? NS  Multiple myeloma cells express B-cell maturation […]

From Recent Issues

How We Treat Left-Sided vs Right-Sided Colon Cancer

  Learning Objectives • To understand the biological and clinical differences between left-sided and right-sided colon cancer; • To identify appropriate therapies for patients with metastatic […]

Providing Oncology Care During the COVID-19 Pandemic

  H&O  What has it been like practicing oncology in Washington state over the past few months? GL  Most of my insights are based on the […]

Strategies to Overcome Resistance to PD-1 Inhibitors

H&O  How do programmed death 1 (PD-1) inhibitors work? TG  There is a growing list of antibodies that target either the PD-1 receptor or the ligand […]


The Evolving Use of Minimal Residual Disease (MRD) Assessment in Chronic Lymphocytic Leukemia

Abstract: The treatment of chronic lymphocytic leukemia (CLL) has changed remarkably throughout the past decade, with patients achieving deeper and more durable responses. Importantly, this clinical activity […]

Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients With Hematologic Malignancies: A Case-Based Monograph

Abstract: New treatments for hematologic malignancies have led to outcomes that are outpacing the ability of traditional measures of response to accurately capture a patient’s depth of […]

Highlights in B-Cell Malignancies From the 61st American Society of Hematology Annual Meeting

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients With Chronic Lymphocytic Leukemia: Extended Follow-Up From the E1912 Trial Chemoimmunotherapy consisting of […]